LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

Search

Fate Therapeutics Inc

Затворен

СекторЗдравеопазване

1.13 -4.24

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.12

Максимум

1.18

Ключови измерители

By Trading Economics

Приходи

15M

-38M

Продажби

-231K

1.6M

EPS

-0.32

Марж на печалбата

-2,309.454

Служители

181

EBITDA

4.3M

-38M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+309.24% upside

Дивиденти

By Dow Jones

Следващи печалби

11.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

24M

146M

Предишно отваряне

5.37

Предишно затваряне

1.13

Настроения в новините

By Acuity

26%

74%

53 / 381 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Fate Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.06.2025 г., 19:24 ч. UTC

Значими двигатели на пазара

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

23.06.2025 г., 19:07 ч. UTC

Значими двигатели на пазара

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

23.06.2025 г., 17:29 ч. UTC

Придобивния, сливания и поглъщания

FTC Resolves Antitrust Probe Into Omnicom-Interpublic Merger

23.06.2025 г., 23:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.06.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Israel-Iran Conflict Ease -- Market Talk

23.06.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Falls After Trump Says Israel, Iran Agree to Cease-Fire -- Market Talk

23.06.2025 г., 23:39 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

23.06.2025 г., 22:53 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

23.06.2025 г., 21:42 ч. UTC

Печалби

KB Home Cuts FY25 Outlook as 2Q Profit, Sales Fall -- Update

23.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

23.06.2025 г., 20:30 ч. UTC

Пазарно говорене

Canada Employment Data May Be Overstating Job Gains -- Market Talk

23.06.2025 г., 20:24 ч. UTC

Придобивния, сливания и поглъщания

Tesla Stock Surges After Musk's Robo-Taxi Rollout. Where Shares Go From Here. -- Barrons.com

23.06.2025 г., 20:16 ч. UTC

Пазарно говорене

U.S. Stocks Climb After Iran's Retaliation Seen As Measured -- Market Talk

23.06.2025 г., 19:22 ч. UTC

Пазарно говорене

Oil Futures Sink As Iranian Retaliation Seen Weak -- Market Talk

23.06.2025 г., 18:56 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower -- Market Talk

23.06.2025 г., 18:49 ч. UTC

Пазарно говорене

Gold Ticks Higher in Cautious Trade -- Market Talk

23.06.2025 г., 18:14 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

23.06.2025 г., 18:14 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Little Changed on Iran's Retaliation -- Market Talk

23.06.2025 г., 17:59 ч. UTC

Пазарно говорене

Oil Futures Fall As Iran Fires Missiles At U.S. Bases in Qatar -- Market Talk

23.06.2025 г., 17:25 ч. UTC

Пазарно говорене

Services Lift Mexico's Economic Activity in April -- Market Talk

23.06.2025 г., 17:22 ч. UTC

Пазарно говорене

Weaker Oil Long-Term Looks to Keep a Lid on Grains -- Market Talk

23.06.2025 г., 17:20 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in Early June --Market Talk -- Market Talk

23.06.2025 г., 16:27 ч. UTC

Пазарно говорене
Печалби

Commercial Metals Says Tariffs, Interest Rates Won't Drag on Earnings -- Market Talk

23.06.2025 г., 16:23 ч. UTC

Пазарно говорене
Печалби

Commercial Metals Sees Resilient Demand, Eyes Growth as Economic Uncertainty Eases -- Market Talk

23.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

23.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

23.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

23.06.2025 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Didn't Disclose Financial Details

23.06.2025 г., 15:49 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: Impact on Credit Agricole's CET1 Ratio Expected to Be Limited

Сравнение с други в отрасъла

Ценова промяна

Fate Therapeutics Inc Прогноза

Ценова цел

By TipRanks

309.24% нагоре

12-месечна прогноза

Среден 4.87 USD  309.24%

Висок 12 USD

Нисък 2 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Fate Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

9 ratings

2

Купи

7

Задържане

0

Продай

Техническа оценка

By Trading Central

0.9101 / 1.14Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

53 / 381 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.